Dynamic Healthcare M&A Database

Acquiring Party	Inverness Medical Innovations, Inc. (AMEX: IMA), a provider of diagnostic products for women's health and chronic disease self-management.
Transferring Party	Clondiag Chip, a German developer of highly sensitive and specific diagnostic tests for rapid point-of-care applications.
Sector	Diagnostics
Date	March 3, 2006
Analysis Expands Inverness' patent portfolio with nucleic acid probes and immunological tests for rapid point-of-care diagnostics. Inverness acquires 67.45% of Clondiag stock for Inverness shares plus $3.1m in cash and agrees to settle obligations of $10m. Inverness will acquiring remaining shares for approximately $4.9m. Additional contingent payments based on new product development milestones.
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 1Q06